Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles matching "Scleroderma, Systemic"

NewsRSSApr 29

Test Your Knowledge About Nintedanib for the Treatment of PPF

This article is a quiz that tests what you know about nintedanib, a medication used to treat progressive pulmonary fibrosis (PPF). Progressive pulmonary fibrosis is a lung disease where lung tissue becomes scarred and stiff over time, making it harder to breathe. The quiz helps patients and caregivers learn more about how this drug works and its role in treatment.

WHY IT MATTERSUnderstanding how nintedanib works can help patients with PPF make informed decisions about their treatment options and have more meaningful conversations with their doctors about managing their condition.
ℹ Good to knowprogressive pulmonary fibrosis
NewsRSSApr 22

Test Your Knowledge About Nerandomilast for the Treatment of PPF

This article is a quiz about nerandomilast, a medicine being studied to treat progressive pulmonary fibrosis (PPF), which is a lung disease where lung tissue becomes scarred and stiff over time, making it harder to breathe. The quiz helps patients and caregivers learn more about this potential treatment option. It's a way to test your understanding of how this medicine might help people with this serious lung condition.

WHY IT MATTERSPatients with progressive pulmonary fibrosis have limited treatment options, so learning about emerging therapies like nerandomilast helps them stay informed about potential new ways to slow lung damage.
ℹ Good to knowprogressive pulmonary fibrosis
PolicyPUBMEDApr 1

Patient partnership model in rare and complex rheumatological conditions: research and beyond in European Reference Network ReCONNET.

A European network for rare connective tissue diseases has created a new model where patients are treated as equal partners in research and care decisions. Instead of doctors alone deciding what to study and how to treat patients, this network includes patients in every step—from identifying problems to writing research papers together. This approach helps address long diagnostic delays and gaps in care that patients with these rare diseases often face.

WHY IT MATTERSPatients with rare connective tissue diseases can now directly influence research priorities and treatment approaches through structured partnership roles, rather than having decisions made without their input.
💬 Ask your doctorrare connective tissue diseasessystemic sclerosissystemic lupus erythematosus

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases